Background/Aims: Many inflammation parameters are associated with obesity, but few comparable data are found in youth. This study aims to characterize the differences in serum levels of 13 biochemical inflammatory markers between boys with increased BMI and boys with normal BMI, and examine the relationships between inflammation markers, skinfold thicknesses, and body composition. Participants/Methods: The participants were 38 boys (BMI above 85th percentile) and 38 boys (normal BMI) at the age of 10–11 years. Measurements included BMI, 9 skinfold thicknesses, waist and hip circumferences, and total body and trunk fat mass and percentage as indices of obesity, fasting insulin, glucose, and serum concentrations of IL-2, IL-4, IL-6, IL-8, IL-10, VEGF, IFN-γ, TNF-α, IL-1α, IL-1β, monocyte chemoattractant protein-1 (MCP-1), epidermal growth factor, and CRP. Results: Overweight boys (OWB) were taller and more frequently in puberty than normal-weight boys (NWB). Skinfold thicknesses and body composition parameters were higher in OWB. They had significantly higher serum IL-6, IL-8, IFN-γ, MCP-1, and CRP values compared to NWB. Conclusions: Six of 13 measured biochemical markers were significantly increased in OWB, indicating that many low-grade inflammatory processes are already involved in the development of obesity in childhood.

1.
Livingstone MBE: Childhood obesity in Europe: a growing concern. Pub Health Nutr 2001;4:109–116.
2.
Todoric J, Strobl B, Jais A, Boucheron N, Bayer M, Amann S, Lindroos J, Teperino R, Prager G, Bilban M, Ellmeier W, Krempler F, Müller M, Wagner O, Patsch W, Pospisilik JA, Esterbauer H: Cross-talk between interferon-γ and hedgehog signaling regulates adipogenesis. Diab 2011;60:1668–1676.
3.
Aygun AD, Gundor S, Ustundag B, Gurgoze MK, Sen Y: Proinflammatory cytokines and leptin are increased in serum of prepubertal obese children. Mediators Inflam 2005;3:180–183.
4.
Ford ES, Ajani UA, Mokdad AH: The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diab Care 2005;28:878–881.
5.
Caballero AE, Bousquet-Santos K, Robles-Osorio L, Montagnani V, Soodini G, Porramatikul S, Hamdy O, Nobrega ACL, Horton ES: Overweight Latino children and adolescents have marked endothelial dysfunction and subclinical vascular inflammation in association with excess body fat and insulin resistance. Diab Care 2008;31:576–582.
6.
Sacheck J: Pediatric obesity: an inflammatory condition? J Parent Ent Nutr 2008;32:633–637.
7.
Sumarac-Dumanovic M, Stevanovic D, Ljubic A, Jorga J, Simic M, Stamenkovic-Pejkovic D, Starcevic V, Trajkovic V, Micic D: Increased activity of interleukin-23/interleukin-17 pro-inflammatory axis in obese women. Int J Obes Relat Metab Disor 2009;33:151–156.
8.
Parrett AL, Valentine RJ, Arngrimsson SA, Castelli DM, Evans EM: Adiposity, activity, fitness, and C-reactive protein in children. Med Sci Sports Exerc 2010;42:1981–1986.
9.
Herder C, Schneitler S, Rathmann W, Haastert B, Schneitler H, Winkler H, Bredahl R, Hahnloser E, Martin S: Low-grade inflammation, obesity, and insulin resistance in adolescents. J Clin Endocrinol Metab 2007;92:4569–4574.
10.
Maffeis C, Manfredi R, Trombetta M, Sordelli S, Storti M, Benuzzi T, Bonadonna RC: Insulin sensitivity is correlated with subcutaneous but not visceral body fat in overweight and obese prepubertal children. J Clin Endocrinol Metab 2008;93:2122–2128.
11.
Arslan N, Erdur B, Aydin A: Hormones and cytokines in childhood obesity. Indian Ped 2010;47:829–839.
12.
Tam CS, Garnett SP, Cowell CT, Heilbronn LK, Lee JW, Wong M, Baur LA: IL-6, IL-8 and IL-10 levels in healthy weight and overweight children. Horm Res Paed 2010;73:128–134.
13.
Glowinska B, Urban M: Selected cytokines (IL-6, IL-8, IL-10, MCP-1, TNF-alpha) in children and adolescents with atherosclerosis risk factors: obesity, hypertension, diabetes. Wiad Lek 2003;56:109–116.
14.
Pacifico L, Di Renzo L, Anania C: Increased T-helper interferon-gamma-secreting cells in obese children. Eur J Endocrinol 2006;154:691–697.
15.
Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Saito Y: Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diab 2003;46:1483–1488.
16.
Loebig M, Klement J, Schmoller A, Betz S, Heuck N, Schweiger U, Peters A, Schultes B, Oltmanns KM: Evidence for a relationship between VEGF and BMI independent of insulin sensitivity by glucose clamp procedure in a homogenous group healthy young men. PloS One 2010;5:e12610.
17.
Roth CL, Kratz M, Ralston MM, Reinehr T: Changes in adipose-derived inflammatory cytokines and chemokines after successful lifestyle intervention in obese children. Metab Clin Experim 2011;60:445–452.
18.
Festa A, D’Agostino R, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM: The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001;25:1407–1415.
19.
Park HS, Park JY, Yu R: Relationships of obesity and visceral adiposity with serum concentrations of CRP, TNFα and IL-6. Diab Res Clin Pract 2005;69:29–35.
20.
Matsudo SMM, Matsudo VKR: Self-assessment and physician assessment of sexual maturation in Brazilian boys and girls: concordance and reproducibility. Am J Hum Biol 1994;6:451–455.
21.
Norton KI, Whittingham N, Carter JEI, Kerr D, Gore C, Marfell-Jones MJ: Measurement techniques in anthropometry; in Norton KI, Olds T (eds): Anthropometrica. Sydney, UNSW Press, 1996, pp 25–75.
22.
Heger S, Koerner A, Meigen C, Gausche R, Keller A, Keller E, Kiess W: Impact of weight status on the onset and parameters of puberty: analysis of three representative cohorts from central Europe. J Ped Endocrinol Metab 2008;21:865–877.
23.
Lee IS, Choue R: The differences in blood levels of lipids, adipokines, and proinflammatory cytokines among normal, overweight, and obese Korean women. Endocrinol 2009;19:267–270.
24.
Claffey KP, Wilkinson WO, Spiegelman BM: Vascular endothelial growth factor regulation by cell differentiation and activated second messenger pathways. J Biol Chem 1992;267:16317–16322.
25.
Alvarez JA, Higgins PB, Oster RA, Fernandez JR, Darnell BE, Gover BA: Fasting and postprandial markers of inflammation in lean and overweight children. Am J Clin Nutr 2009;89:1138–1144.
26.
Pradham AD, Manson JAE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327–334.
27.
Völler H, Schmailzl KJG, Bjarnason-Wehrens B: Obesity and cardiovascular diseases – theoretical background and therapeutic consequences (in German). Z Kardiol 2004;93:503–513.
28.
Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE: Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001;9:414–417.
29.
Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circ 2000;101:1767–1772.
30.
Petersen AMW, Pedersen BK: The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 2006;57:43–51.
31.
Fried SK, Bunkin DA, Greenberg AS: Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847–850.
32.
Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196–4200.
33.
Reinehr T, Stoffel-Wagner B, Roth CL, Andler W: High-sensitive C-reactive protein, tumor necrosis factor α, and cardiovascular risk factors before and after weight loss in obese children. Metab Clin Experim 2005;54:1155–1161.
34.
McLaughlin T, Abassi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P: Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circ 2002;106:2908–2912.
35.
Ford ES, Galuska DA, Gillespie C, Will JC, Giles WH, Dietz WH: C-reactive protein and body mass index in children: findings from the Third National Health and Nutrition Examination Survey, 1988–1994. J Pediatr 2001;138:486–492.
36.
Hiura M, Kikuchi T, Nagasaki K, Uchiyama M: Elevation of serum C-reactive protein levels is associated with obesity in boys. Hypertens Res 2003;26:541–546.
37.
Sardinha LB, Teixeira PJ, Guedes DP, Going SB, Lohman TG: Subcutaneous central fat is associated with cardiovascular risk factors in men independently of total fatness and fitness. Metab Clin Experim 2000;49:1379–1385.
38.
Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, O’Donnell CJ, Fox CS: Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, heart study and vascular calcification in a community-based sample: the Framingham heart study. Circulation 2008;117:605–613.
39.
McCarthy HD: Body fat measurements in children as predictors for the metabolic syndrome: focus on waist circumference. Proc Nutr Soc 2006;65:385–392.
40.
Teixeira PJ, Sardinha LB, Going SB, Lohman TG: Total and regional fat and serum cardiovascular disease risk factors in lean and obese children and adolescents. Obes Res 2001;9:432–442.
41.
Kaul S, Rothney MP, Peters DM, Wacker WK, Davis CE, Shapiro MD, Ergun DL: Dual-energy X-ray absorptiometry for quantification of visceral fat. Obesity (Silver Spring) 2012;20:1313–1318.
42.
De Jongh RT, Ijzerman RG, Serne EH, Voordouw JJ, Yudkin JS, Delemarre-van de Waal HA, Stehouwer CDA, van Weissenbruch MM: Visceral and truncal subcutaneous adipose tissue are associated with impaired capillary recruitment in healthy individuals. J Clin Endocrinol Metab 2006;91:5100–5106.
43.
Hermsdorff HH, Puchau B, Zulet MA, Martínez JA: Association of body fat distribution with proinflammatory gene expression in peripheral blood mononuclear cells from young adult subjects. OMICS 2010;14:297–307.
44.
Jürimäe J, Jürimäe T, Ring-Dimitriou S, LeMura LM, Arciero PJ, von Duvillard SP: Plasma adiponectin and insulin sensitivity in overweight and normal-weight middle-aged premenopausal women. Metab Clin Experim 2009;58:638–643.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.